147 related articles for article (PubMed ID: 38738771)
1. Vogt-Koyanagi-Harada Syndrome Following COVID-19 mRNA Vaccination: Th2 to Th1 Transition-related Molecular Machinery.
Ikuno Y; Yamaguchi A; Takahashi T; Fujimoto N
Acta Derm Venereol; 2024 May; 104():adv21502. PubMed ID: 38738771
[No Abstract] [Full Text] [Related]
2. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
Koong LR; Chee WK; Toh ZH; Ng XL; Agrawal R; Ho SL
Ocul Immunol Inflamm; 2021 Aug; 29(6):1212-1215. PubMed ID: 34505819
[TBL] [Abstract][Full Text] [Related]
3. Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
Sato T; Nihei R; Sora D; Nishio Y; Takeuchi M
Front Immunol; 2022; 13():967972. PubMed ID: 36248859
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
Rujkorakarn P; Patamatamkul S
J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
[TBL] [Abstract][Full Text] [Related]
6. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
[TBL] [Abstract][Full Text] [Related]
7. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
[TBL] [Abstract][Full Text] [Related]
8. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
9. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
10. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.
Simone A; Herald J; Chen A; Gulati N; Shen AY; Lewin B; Lee MS
JAMA Intern Med; 2021 Dec; 181(12):1668-1670. PubMed ID: 34605853
[TBL] [Abstract][Full Text] [Related]
11. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
[TBL] [Abstract][Full Text] [Related]
12. Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series.
Pillar S; Weinberg T; Amer R
Int Ophthalmol; 2023 May; 43(5):1677-1686. PubMed ID: 36316618
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.
Matsuo T; Masuda I; Ota K; Yamadori I; Sunami R; Nose S
Acta Med Okayama; 2007 Oct; 61(5):305-9. PubMed ID: 17971847
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
[TBL] [Abstract][Full Text] [Related]
15. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.
Kim SY; Kang MS; Kwon HJ
Ocul Immunol Inflamm; 2022 Jul; 30(5):1218-1221. PubMed ID: 35113750
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
17. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
18. Rapid induction of antigen-specific CD4
Painter MM; Mathew D; Goel RR; Apostolidis SA; Pattekar A; Kuthuru O; Baxter AE; Herati RS; Oldridge DA; Gouma S; Hicks P; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Bates P; Hensley SE; Grifoni A; Weiskopf D; Sette A; Greenplate AR; Wherry EJ
Immunity; 2021 Sep; 54(9):2133-2142.e3. PubMed ID: 34453880
[TBL] [Abstract][Full Text] [Related]
19.
Brunet de Courssou JB; Tisseyre M; Hadjadj J; Chouchana L; Broca F; Terrier B; Duraffour P; Henriquez S
Ocul Immunol Inflamm; 2022 Jul; 30(5):1292-1295. PubMed ID: 35113742
[TBL] [Abstract][Full Text] [Related]
20. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
Damico FM; Cunha-Neto E; Goldberg AC; Iwai LK; Marin ML; Hammer J; Kalil J; Yamamoto JH
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]